

Athanasios Argiris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9132645/publications.pdf>

Version: 2024-02-01

152
papers

9,318
citations

38720

50
h-index

42364

92
g-index

154
all docs

154
docs citations

154
times ranked

11349
citing authors

#	ARTICLE	IF	CITATIONS
1	Head and neck cancer. <i>Lancet</i> , The, 2008, 371, 1695-1709.	6.3	1,732
2	Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 56-62.	0.8	259
3	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	217
4	The impact of health insurance status on the survival of patients with head and neck cancer. <i>Cancer</i> , 2010, 116, 476-485.	2.0	211
5	Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1219-1230.	0.4	190
6	Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1405-1414.	0.8	188
7	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. <i>Journal of Immunological Methods</i> , 2012, 381, 14-22.	0.6	185
8	Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 3605-3610.	3.2	183
9	Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. <i>Cancer</i> , 2004, 101, 2222-2229.	2.0	170
10	Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1493-1500.	0.4	165
11	Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 1956-1962.	3.2	159
12	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.3	157
13	Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. <i>Cancer</i> , 2008, 113, 1446-1452.	2.0	147
14	Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 70.	3.8	141
15	A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1757-1760.	0.5	138
16	Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 262-268.	0.8	134
17	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5294-5300.	0.8	132
18	Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. <i>Head and Neck</i> , 2004, 26, 447-455.	0.9	130

#	ARTICLE	IF	CITATIONS
19	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2013, 24, 220-225.	0.6	127
20	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	126
21	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017, 7, 72.	1.3	122
22	Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5900-5907.	3.2	121
23	Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2433-2444.	3.2	118
24	Deferring Planned Neck Dissection Following Chemoradiation for Stage IV Head and Neck Cancer: The Utility of PETâ€CT. <i>Laryngoscope</i> , 2007, 117, 2129-2134.	1.1	115
25	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1140-1145.	0.8	112
26	The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 372-379.	0.6	107
27	Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics. <i>Food and Chemical Toxicology</i> , 2016, 91, 42-57.	1.8	107
28	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 766-770.	1.5	106
29	Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. <i>Annals of Oncology</i> , 2014, 25, 1410-1416.	0.6	89
30	Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 408-416.	1.6	84
31	Epidemiology, Staging, and Screening of Head and Neck Cancer. , 2003, 114, 15-60.		79
32	Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. <i>Annals of Oncology</i> , 2016, 27, 318-323.	0.6	77
33	Progress in the therapy of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 119-133.	2.0	73
34	Esthesioneuroblastoma: The Northwestern University Experience. <i>Laryngoscope</i> , 2003, 113, 155-160.	1.1	71
35	Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). <i>Clinical Cancer Research</i> , 2004, 10, 1409-1420.	3.2	70
36	Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3266-3274.	0.8	70

#	ARTICLE	IF	CITATIONS
37	Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2278-2289.	3.2	67
38	Staging and Monitoring of Small Cell Lung Cancer Using [18F]Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (FDG-PET). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 45-50.	0.6	66
39	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, 1235-1242.	0.8	63
40	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 122.	1.3	63
41	A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. <i>Cancer</i> , 2011, 117, 3374-3382.	2.0	62
42	Planned Post-Chemoradiation Neck Dissection: Significance of Radiation Dose. <i>Laryngoscope</i> , 2006, 116, 33-36.	1.1	61
43	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 358-365.	1.1	61
44	Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. <i>Annals of Oncology</i> , 2008, 19, 1787-1794.	0.6	60
45	A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Human Gene Therapy</i> , 2011, 22, 336-342.	1.4	60
46	Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5936-43.	3.2	59
47	Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Non-Small Cell Lung Cancer: A SEER Cohort Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 722-727.	0.7	58
48	Targeting angiogenesis in head and neck cancer. <i>Oral Oncology</i> , 2015, 51, 409-415.	0.8	57
49	Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. <i>Annals of Oncology</i> , 2010, 21, 2278-2283.	0.6	53
50	Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners. <i>Head and Neck</i> , 2015, 37, 1282-1289.	0.9	53
51	Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. <i>Annals of Oncology</i> , 2003, 14, 1306-1311.	0.6	52
52	Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5755-5764.	3.2	51
53	XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2011, 17, 5513-5522.	3.2	50
54	Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1759-1764.	0.9	50

#	ARTICLE	IF	CITATIONS
55	Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2004, 43, 317-322.	0.9	48
56	Erlotinib, Erlotinib+Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3289-3298.	3.2	48
57	Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. <i>Annals of Oncology</i> , 2016, 27, 1594-1600.	0.6	48
58	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 145-151.	0.5	48
59	Update on chemoradiotherapy for head and neck cancer. <i>Current Opinion in Oncology</i> , 2002, 14, 323-329.	1.1	47
60	Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. <i>Annals of Oncology</i> , 2007, 18, 1224-1229.	0.6	47
61	The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. <i>Clinical Cancer Research</i> , 2008, 14, 2088-2094.	3.2	47
62	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2011, 47, 961-966.	0.8	47
63	Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure. <i>Oncologist</i> , 2003, 8, 350-360.	1.9	45
64	A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. <i>Investigational New Drugs</i> , 2008, 26, 183-188.	1.2	45
65	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	5.1	45
66	Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1096-1106.	0.4	44
67	Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2015, 37, 1665-1671.	0.9	43
68	High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. <i>Annals of Oncology</i> , 2000, 11, 665-672.	0.6	42
69	Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. <i>Head and Neck</i> , 2011, 33, 318-323.	0.9	39
70	Long-Term Results of a Phase III Randomized Trial of Postoperative Radiotherapy With or Without Carboplatin in Patients With High-Risk Head and Neck Cancer. <i>Laryngoscope</i> , 2008, 118, 444-449.	1.1	37
71	Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group. <i>Head and Neck</i> , 2013, 35, 942-948.	0.9	36
72	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2017, 123, 2936-2944.	2.0	36

#	ARTICLE	IF	CITATIONS
73	Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience. <i>Laryngoscope</i> , 2010, 120, 71-75.	1.1	35
74	A randomized phase II study of ixabepilone (BMS-247550) given daily 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. <i>Annals of Oncology</i> , 2008, 19, 977-983.	0.6	34
75	Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. <i>Clinical Cancer Research</i> , 2014, 20, 5041-5051.	3.2	33
76	A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 574-578.	0.5	32
77	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. <i>Cancer Epidemiology</i> , 2016, 42, 46-52.	0.8	32
78	A phase 2 study of dalantercept, an activin receptor-like kinase ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3641-3649.	2.0	32
79	An update on angiogenesis targeting in head and neck squamous cell carcinoma. <i>Cancers of the Head & Neck</i> , 2020, 5, 5.	6.2	31
80	Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. <i>Annals of Oncology</i> , 2016, 27, 2257-2262.	0.6	29
81	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1289-1301.	1.1	29
82	PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 563-566.	0.6	26
83	Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 4996-5004.	3.2	26
84	Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. <i>Anticancer Research</i> , 2013, 33, 4475-81.	0.5	26
85	Targeting growth factors and angiogenesis; using small molecules in malignancy. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 279-292.	2.7	25
86	Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. <i>Annals of Oncology</i> , 2010, 21, 145-151.	0.6	25
87	Induction Chemotherapy for Head and Neck Cancer: Will History Repeat Itself?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 393-403.	2.3	24
88	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007, 16, 1615-1626.	1.5	24
89	Docetaxel and irinotecan in recurrent or metastatic head and neck cancer. <i>Cancer</i> , 2009, 115, 4504-4513.	2.0	24
90	Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. <i>Frontiers in Oncology</i> , 2020, 10, 566315.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Abnormalities of Serum Amylase and Lipase in Hiv-Positive Patients. <i>American Journal of Gastroenterology</i> , 1999, 94, 1248-1252.	0.2	23
92	Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer. <i>Cancer Biology and Therapy</i> , 2002, 1, 646-651.	1.5	22
93	Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 4922-4932.	3.2	21
94	Cetuximab-induced aseptic meningitis. <i>Annals of Oncology</i> , 2009, 20, 1609-1610.	0.6	21
95	Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 419.	1.3	19
96	Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 915-927.	3.2	19
97	Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2006, 24, 203-212.	1.2	18
98	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 33-37.	1.1	18
99	Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 1575-1584.	1.2	17
100	Empowering induction therapy for locally advanced head and neck cancer. <i>Annals of Oncology</i> , 2011, 22, 773-781.	0.6	15
101	Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 221-230.	0.7	15
102	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102192.	3.4	15
103	Can Current Treatments for Advanced Non-Small-Cell Lung Cancer Be Improved?. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 499.	3.8	15
104	EGFR inhibition for recurrent or metastatic HNSCC. <i>Lancet Oncology</i> , The, 2015, 16, 488-489.	5.1	14
105	Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). <i>Annals of Oncology</i> , 2017, 28, 3037-3043.	0.6	14
106	Pemetrexed: a novel antifolate agent enters clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 511-522.	1.1	13
107	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. <i>Journal of Thoracic Oncology</i> , 2006, 1, 52-60.	0.5	13
108	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021, 159, 194-204.	1.3	13

#	ARTICLE	IF	CITATIONS
109	Mycobacterium avium Complex Inclusions Mimicking Gaucher's Cells. <i>New England Journal of Medicine</i> , 1999, 340, 1372-1372.	13.9	12
110	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. <i>Annals of Oncology</i> , 2011, 22, 2482-2488.	0.6	12
111	Pemetrexed in head and neck cancer: A systematic review. <i>Oral Oncology</i> , 2013, 49, 492-501.	0.8	12
112	Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 6583-6583.	0.8	12
113	Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. <i>Investigational New Drugs</i> , 2001, 19, 321-326.	1.2	11
114	Targeting Angiogenesis from Premalignancy to Metastases. <i>Cancer Prevention Research</i> , 2009, 2, 291-294.	0.7	11
115	Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: A pilot randomized trial in head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1136-1145.	0.8	11
116	A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). <i>Clinical Lung Cancer</i> , 2021, 22, 313-323.e1.	1.1	11
117	Clinical Applications of Gene Therapy in Head and Neck Cancer. <i>Current Gene Therapy</i> , 2007, 7, 446-457.	0.9	10
118	Current status and future directions in induction chemotherapy for head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 57-74.	2.0	10
119	Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. <i>Journal of Thoracic Oncology</i> , 2006, 1, 52-60.	0.5	10
120	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 175-186.	2.0	9
121	p53-Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study. <i>Molecular Oncology</i> , 2016, 10, 148-156.	2.1	9
122	T2 relaxation times of irradiated vertebral bone marrow in patients with seminoma. <i>Magnetic Resonance Imaging</i> , 1997, 15, 335-340.	1.0	8
123	Malignant Thymoma Associated With Fatal Myocarditis and Polymyositis in a 32-Year-Old Woman With a History of Hairy Cell Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 213-214.	0.6	8
124	Phase 1 study of EGFR antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlates. <i>Cancer</i> , 2018, 124, 3881-3889.	2.0	8
125	Radiotherapy effects on vertebral bone marrow: Easily recognizable changes in T2 relaxation times. <i>Magnetic Resonance Imaging</i> , 1996, 14, 633-638.	1.0	7
126	Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 6000-6000.	0.8	7

#	ARTICLE	IF	CITATIONS
127	Revisiting induction chemotherapy for head and neck cancer. <i>Oncology</i> , 2005, 19, 759-70.	0.4	7
128	Molecular strategies and 111in-labelled somatostatin analogues in defining the management of neuroendocrine tumour disease: a new paradigm for surgical management. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2003, 1, 137-143.	0.8	6
129	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. <i>Journal of Thoracic Oncology</i> , 2006, 1, 52-60.	0.5	6
130	Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682075.	1.3	6
131	Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302). <i>Cancer Medicine</i> , 2020, 9, 8884-8894.	1.3	5
132	Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6016-6016.	0.8	5
133	Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era. <i>Cancers</i> , 2022, 14, 1202.	1.7	5
134	Pathologic and radiographic responses in a window of opportunity for durvalumab plus metformin trial for squamous cell carcinoma of the head and neck (HNSCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6068-6068.	0.8	4
135	Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6022-6022.	0.8	4
136	Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6070-6070.	0.8	4
137	Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein-Barr Virus DNA after Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	4
138	Update on the Role of EGFR Inhibitors in Cancer Therapeutics. <i>Cancer Treatment and Research</i> , 2007, 135, 257-275.	0.2	3
139	S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8523-8523.	0.8	3
140	Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6070-6070.	0.8	3
141	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. <i>Cancer Treatment Reviews</i> , 2022, 109, 102437.	3.4	3
142	Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer. <i>Current Cancer Research</i> , 2018, , 439-467.	0.2	1
143	Revisiting induction chemotherapy for head and neck cancer. <i>References and reviews. Oncology</i> , 2005, 19, 932-4, 939; discussion 939-45.	0.4	1
144	Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 611-9.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 175-175.	2.0	0
146	Growth and Molecular Interactions between Tamoxifen and Trastuzumab. <i>Clinical Cancer Research</i> , 2005, 11, 3597-3597.	3.2	0
147	The Contribution of Chemotherapy. <i>Medical Radiology</i> , 2009, , 203-214.	0.0	0
148	Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1190.	1.3	0
149	New and Promising Targeted Therapies in First and Second-Line Settings. , 2021, , 277-296.		0
150	Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas. , 2009, , 297-307.		0
151	P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial. <i>Blood</i> , 2014, 124, 4809-4809.	0.6	0
152	Immune-related gene expression signature in patients with recurrent/metastatic head and neck cancer treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6051-6051.	0.8	0